#WCD2019

AEDV HIGHLIGHTS

24th World Congress of Dermatology (WCD)

10-15 JUNIO 2019

Milàn

Patrocina:

janssen Immunology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson

Organiza:

ACADEMIA ESPAÑOLA DE DERMATOLOGÍA Y VENEREOLOGÍA
AEDV 1909

AEDV HIGHLIGHTS

24th World Congress of Dermatology (WCD)

10-15 JUNIO 2019

Milán

Dermatitis atópica

Dr. Pablo de la Cueva

Hospital Universitario Infanta Leonor

Patrocina: Janssen Immunology, Pharmaceutical Companies of Johnson & Johnson

Organiza: AEDV Academia Española de Dermatología y Venereología

Atopic dermatitis. Graham Ogg



FLG=filaggrin.

1. Gittler JK, et al. *J Allergy Clin Immunol*. 2012;130(6):1344-1354. 2. Suárez-Fariñas M, et al. *J Allergy Clin Immunol*. 2013;132(2):361-370. 3. Kezic S, et al. *Allergy*. 2011;66(7):934-940. 4. Czarnowicki T, et al. *J Allergy Clin Immunol*. 2015;136(4):941-951. 5. Noda S, et al. *J Allergy Clin Immunol*. 2015;135(2):324-336.

Milàn

Atopic dermatitis. Emma Guttman





- Biologic
  - Anti-IL4/13: dupilumab
  - Anti-IL13: tralokinumab, lebrikizumab.
  - Anti- IL31: nemolizumab.
  - Anti-IL31 y anti-OncostatinM: KPL-716.
  - Anti-IL22: ILV-094.
  - Anti-OX40: GBR830, KHK4083.
  - Anti-IL17C: MOR-106.
  - Anti-IL33: ANB020.
- Oral:
  - JAK Inhibitors: baricitinib (1,2), upadacitinib (1), abrocitinib (1), ASN002 (JAK/SIK).
  - Anti-H4R: ZPL-389

Milàn



Valeria Aoki

PDE4 Inhibitors and AD

JAK Inhibitors and AD

AMPs and AD

Prostaglandin leukotriene inhibitors and AD

TRPV1 Inhibitors and AD

Milàn

Valeria Aoki

PDE4 Inhibitors and AD

Name	Primary endpoint	Phase	Trial #	N
PDE4 inhibitors:				
• Crisaborole	• ISGA d29 • ADSI/interv-adherence	• III/IV	• NCT02118792/02118766/010301508/030250663	• 763 (>2yo), 764 (>2yo) 46A, 40A
• DRM02			• NCT01993420	• 21A
• OPA-15406	• Phys les assess	• II	• NCT02068352	• 121 (12-70 yo)
	• Sev AE,% Sucess IGA	• II		
• Roflumilast	• Bas d15/SCORAD	• II	• NCT01856764	• 40A
• E6005/RVT-501	• Pharm/pruritus-EASI/Sev AE	• I/II • II	• NCT01179880/NCT146941/NCT02950922	• 76A, 78A, 157 (12-70 yo
• Leo-29102	• EASI –wk 4	• II	• NCT01037881	• 183A

(Nygaard U et al, Dermatology 2017;Napolitano M et al 2018, Exp Rev Clin Pharm; Moyle M et al 2019 Exp Dermat

Valeria Aoki

JAK Inhibitors and AD

Name	Primary endpoint	Phase	Trial #	N
JAK inhibitors:				
• Ruxolitinib (JAK1/2)	• EASI –wk 4	• II/III	• NCB018424	• 307A
• Tofacitinib (JAK1/3)		• II	• NCT02001181	• 69A
• LEO124249 (JAK1/2/3/TYK2)	• EASI –wk 4	• II/III		• 327A

Momelotinib (MMB-mouse model)

(Bissonette R et al 2016 BJD;Nygaard U et al, Dermatology 2017;Napolitano M et al 2018, Exp Rev Clin Pharm); Moyle M et al 2019 Exp De

Valeria Aoki

Antimicrobial peptides and AD

Name	Primary endpoint	Phase	Trial #	N
AMPs				
• Omiganan pentahydrochloride (synthetic cationic peptide)	• pharm/saf/tol	• II	• NCT02456480	• 37 A
	• Clin SCORAD	• II	• NCT03091426	• 80 A
• Tapinarof (AhR)	• IGA wk12	• II	• NCT02564055	• 247 (>12yo)

(Nygaard U et al, Dermatology 2017;Napolitano M et al 2018, Exp Rev Clin Pharm); Moyle M et al 2019 Exp Dermatol)

Valeria Aoki

Prostaglandin/Leukotriene Inhibitors and AD

Q301: 5-lipoxygenase inhibitor

- BID, 8 wk, double –blinded, vehicle-controlled
- 57 moderate to severe AD > 18 yo

ZPL-521: cPLA2 inhibitor

- 1% 2 wk, double –blinded, vehicle-controlled
- 57 moderate to severe AD > 18 yo

TRVP1 Inhibitors and AD

Name	Primary endpoint	Phase	Trial #	N
TRVP1 inhibitors:				
• PAC 14028	• SCORAD 4 wk/IGA wk8	• III/IV	• NCT02583022/NCT02757729	• 74A, 192A
• CT1327 (Creabilis)	• Change pruritus/VAS	• II	• NCT01808157	• 188 >12 yo

Milàn

Real-World Effectiveness of Dupilumab in Atopic Dermatitis (AD): Improvement in AD Signs as Assessed by the Investigator Global Assessment (IGA) in an Electronic Medical Records Dataset

Lawrence F. Eichenfield[1], April W. Armstrong[2], Abhijit Gadkari[3], Raymond Miao[4], Chi-Chang Chen[5], Dionne M. Hines[5], Catherine McGuiness[5], Zhen Chen[3], Mandeep Kaur[6], Andrew Korotzer[3], Usha G. Mallya[6]

Figure 2. Pre-post IGA change (n, %) in patients with moderate-to-severe AD, n=187



Dupilumab in real-world clinical practice: efficacy and safety in patients with moderate to severe atopic dermatitis

S. M. Ferrucci[1], S. Tavecchio[1,2], F. Germiniasi[1], C. Moltrasio[1], L. Angileri[1], E. Berti[1,2]

Figure 2. Score improvement at week 16 (n=49)

Erythroderma: a prospective study with 305 patients from Brazil

Denis Miyashiro, Jade Cury-Martins, José Antonio Sanches

Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil





Fig.2. Ages at diagnosis according to the etiologies



Fig.3. Total IgE at diagnosis according to the etiologies

AEDV HIGHLIGHTS

24th World Congress of Dermatology (WCD)

10-15 JUNIO 2019

Milán

Urticaria

Dr. Pablo de la Cueva

Hospital Universitario Infanta Leonor

Patrocina: Janssen Immunology, Pharmaceutical Companies of Johnson & Johnson

Organiza: AEDV Academia Española de Dermatología y Venereología 1909

Chronic urticaria. Treatment of the future (Ana Giménez Arnau)







Milàn

Chronic urticaria. Pregnacy and lactation (Emek Kocaturk)









Milàn

Chronic urticaria. Pregnacy and lactation (Emek Kocaturk)








CILAD
MADRID
9-12 SEPTIEMBRE
2020
23 CONGRESO IBERO LATINO-AMERICANO
DE DERMATOLOGÍA
CILAD 2020: Todos bajo una misma piel
www.cilad2020.com

Milàn